Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target

Benzinga Newsdesk www.benzinga.com Positive 69.1%

Neg 0% Neu 0% Pos 69.1%

Benchmark analyst Robert Wasserman upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $185 price target.